Slovak company created antibodies that prevent multiplication of the coronavirus

The company is developing a vaccine as well.

This 2020 electron microscopic image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles, which cause COVID-19, isolated from a patient in the U.S.This 2020 electron microscopic image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles, which cause COVID-19, isolated from a patient in the U.S. (Source: SITA)

The biotechnology company Axon Neuroscience successfully tested the first therapeutic antibodies on a live SARS-Cov-2 virus in a clinical trial in cooperation with the Biomedical Research Centre of the Slovak Academy of Sciences (SAV).

SkryťTurn off ads
Article continues after video advertisement
SkryťTurn off ads
Article continues after video advertisement

During the development of the COVIDAX vaccine against COVID-19, the
the company was able to develop antibodies that can effectively prevent the multiplication of the SARS-CoV-2 virus.

Slovak company reports positive preclinical results for COVID-19 vaccine Read more 

The trials took place in the Virological Institute of SAV. The results of these tests on the live virus showed that antibodies succeeded in preventing the interaction of the virus with the host cell and subsequent multiplication.

SkryťTurn off ads

“We observed very unequivocal neutralisation activity with several samples,” said virologist Boris Klempa of SAV, as quoted by TASR.

Drugs and vaccine

By using antibodies that have proven effective in several
independent trials, it was possible to map the vulnerable sections of the virus that are accessible to the immune system.

“Through these steps, we focused on the process of humanisation and then started the production,” explained Norbert Žilka, the scientific director of Axon, as quoted by the TASR newswire. He added that these steps must be taken before clinical trials can begin.

In addition to the COVIDAX vaccine, the company's ambition is to introduce drugs that can stop or alleviate the course of the infectious COVID-19 virus to the market.

SkryťTurn off ads

Read more about the coronavirus outbreak in Slovakia:

Top stories

The New Stations of the Cross combine old and new.

New Stations of the Cross to combine surviving remains and contemporary architecture.


Píšem or pišám?

"Do ľava," (to the left) I yelled, "Nie, do prava" (no, to the right), I gasped. "Dolšie," I screamed. "Nie, nie, horšie..." My Slovak girlfriend collapsed in laughter. Was it something I said?


Matthew J. Reynolds
Czech biochemist Jan Konvalinka.

Jan Konvalinka was expecting a pandemic before Covid-19 came along.


SkryťClose ad